Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612430 · ClinicalTrials.gov registry record · Phase 2
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00612430 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 59 participants.
The verdict
NCT00612430, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
Primary Objective to estimate 6-month progression free survival probability of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab. Secondary Objectives To evaluate safety \& tolerability of Etoposide + Bevacizumab among patients with recurrent malignant glioma (RMG). To evaluate radiographic response, progression free survival \& overall survival of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab.
Interventions
- DRUG Bevacizumab and Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612430
The ClinicalTrials.gov registry entry for NCT00612430 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab and Etoposide is the first listed.
NCT00612430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612430 about?
NCT00612430 is a clinical study titled "Ph II Bevacizumab + Etoposide for Pts w Recurrent MG". Primary Objective to estimate 6-month progression free survival probability of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab. Secondary Objectives To evaluate safety \& tolerability of Etoposide + Bevacizumab among patients with recurrent malignant glioma (RMG). To ...
What is the current status of trial NCT00612430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2007-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00612430?
The interventions under investigation include: Bevacizumab and Etoposide (DRUG).
Who is sponsoring clinical trial NCT00612430?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.